<SEC-DOCUMENT>0001104659-19-069217.txt : 20191203
<SEC-HEADER>0001104659-19-069217.hdr.sgml : 20191203
<ACCEPTANCE-DATETIME>20191203075053
ACCESSION NUMBER:		0001104659-19-069217
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20191203
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191203
DATE AS OF CHANGE:		20191203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		191264655

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a19-24358_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> December&nbsp;3, 2019</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">PROTAGONIST THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">001-37852</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">98-0505495</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other   jurisdiction<br>   of incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission<br>   File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer<br>   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Protagonist Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7707 Gateway Blvd., Suite&nbsp;140</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Newark, California 94560-1160</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices, including zip code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(510) 474-0170</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not Applicable</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former name or former address, if changed since last report.)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.0pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.0pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.0pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.0pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of the Act:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Title&nbsp;of&nbsp;each&nbsp;class</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="28%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:28.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Trading&nbsp;Symbol(s)</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.48%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Name&nbsp;of&nbsp;each&nbsp;exchange&nbsp;on&nbsp;which&nbsp;registered</font></b></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common Stock, par value   $0.00001</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PTGX</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.48%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Nasdaq Stock   Market, LLC</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emerging growth company&nbsp;</font><font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;</font><font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\111369\19-24358-1\task9551525\24358-1-ba.htm',USER='111369',CD='Dec  3 09:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;8.01. Other Events.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On December&nbsp;3, 2019, Protagonist Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) issued a press release announcing preliminary Phase 2 results with hepcidin mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. A copy of the press release titled &#147;Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia&#148; is attached hereto as Exhibit&nbsp;99.1 and incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company will host a conference call to discuss the preliminary results from this clinical trial on December&nbsp;3, 2019 at 8:30 a.m.&nbsp;Eastern Time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;9.01. Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)&nbsp;Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="96%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:88.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a19-24358_1ex99d1.htm#Exhibit99_1_092043" title="Click to goto ">Press release, dated December&nbsp;3, 2019, titled   &#147;Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin   Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia&#148;.</a></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_073838_2850"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\jms\111369\19-24358-1\task9551525\24358-1-ba.htm',USER='111369',CD='Dec  3 09:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Protagonist   Therapeutics,&nbsp;Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:   December&nbsp;3, 2019</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="9" style="height:6.75pt;">
<td width="6%" height="9" valign="top" style="height:6.75pt;padding:0in 0in 0in 0in;width:6.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" height="9" valign="top" style="height:6.75pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" height="9" valign="top" style="height:6.75pt;padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Don Kalkofen</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Don Kalkofen</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>    </td>   </tr>
<tr height="0">
<td width="42" style="border:none;"></td>
<td width="313" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="328" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_073933_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\jms\111369\19-24358-1\task9551525\24358-1-ba.htm',USER='111369',CD='Dec  3 09:23 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a19-24358_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>







  </head>
<body link=blue lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1<a name="Exhibit99_1_092043"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="217" height="56" src="g243581mmi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#151; Dose-related reductions in serum iron and transferrin saturation levels provide first evidence of pharmacodynamic effects in patients &#151;</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NEWARK, Calif.,&nbsp;Dec.&nbsp;3, 2019&nbsp;&#151;&nbsp;Protagonist Therapeutics,&nbsp;Inc. (Nasdaq:PTGX) today announced preliminary results from patients with transfusion-dependent (TD) beta-thalassemia in the ongoing TRANSCEND Phase 2 open-label study of PTG-300. Dose-related drug exposure and reductions from baseline serum iron and transferrin saturation (TSAT) levels were observed, with significant reductions at the 40 mg and 80 mg weekly doses (p &lt; 0.02 for each assessment, see graphs below).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="521" height="325" src="g243581mmi002.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\111369\19-24358-1\task9551525\24358-1-mm.htm',USER='111369',CD='Dec  3 09:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="514" height="320" src="g243581mmi003.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;The dose-related pharmacodynamic responses in serum iron and TSAT levels observed in this preliminary analysis provide the first evidence of the effects of PTG-300 in patients with beta-thalassemia, who have highly elevated levels of iron in the body,&#148; commented Samuel Saks, M.D., Protagonist Chief Medical Officer. &#147;These early results suggest the potential of finding an appropriate dose of PTG-300 for continued development in the treatment of beta-thalassemia. While we have observed clinical responders in the study based on the pre-specified criteria of reductions in transfusion burden, continued evaluation at higher doses will be required to evaluate the rate and durability of these effects in order to reach definitive conclusions. We look forward to the results from further study with additional dose regimens and longer follow-up, with clinical efficacy results expected in 2020.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Treatment options for patients with beta-thalassemia are limited and the complications associated with transfusion are serious,&#148; commented Ashutosh Lal, M.D., Program Director of the Comprehensive Thalassemia Center at the UCSF Benioff Children&#146;s Hospital, Oakland, and PTG-300 beta-thalassemia study investigator. &#147;The TRANSCEND trial is examining whether constraining iron availability improves endogenous hemoglobin synthesis in patients with beta-thalassemia, an endpoint for which there exists considerable preclinical evidence. These results demonstrating the pharmacodynamic activity of PTG-300 in reducing TSAT, though preliminary, warrant continued evaluation of PTG-300 for the potential treatment of beta-thalassemia.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;The consistent and significant effect on iron levels observed in normal healthy volunteers in a previous study, and now in patients with beta-thalassemia, provides strong rationale for potential utility of PTG-300 in blood disorders directly dependent on disruption of normal iron homeostasis in the body,&#148; commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. &#147;We are encouraged by these findings and are continuing with </font>our original plans of conducting clinical proof-of-concept studies with PTG-300 in different blood disorders such as beta-thalassemia, polycythemia vera, hereditary hemochromatosis, and an investigator sponsored study in myelodysplastic syndromes. We are well financed to conduct these studies and our corporate objective is to make data-driven decisions in 2020, with the intent of choosing our first clinical indication for a potential pivotal study to begin in 2021.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\111369\19-24358-1\task9551525\24358-1-mm.htm',USER='111369',CD='Dec  3 09:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the study, PTG-300 was well-tolerated and systemic adverse events were mild to moderate in severity and were typical of patients with TD beta-thalassemia. These events were not dose-related and did not prevent dose escalation. There was one serious adverse event of vomiting and confusion, and the most frequent treatment emergent adverse event observed was transient erythema in 4 out of 33 patients (12 percent).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Conference Call and Webcast Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Protagonist will host a conference call at&nbsp;8:30 a.m.&nbsp;EST&nbsp;today,&nbsp;Dec.&nbsp;3, 2019. To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and refer to conference ID number 1662899. The call will also be webcast and will be accessible from &#147;Events&nbsp;&amp; Presentations&#148; in the Investors section of the Company&#146;s website at&nbsp;www.protagonist-inc.com. A replay will be available on the Company&#146;s website following the call.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About the Phase 2 TRANSCEND Study</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The global Phase 2 study is a single-arm, open label, multiple-ascending dose design that will evaluate safety, proof-of-concept and dose finding in adolescent and adult patients with anemia associated with non-transfusion-dependent (NTD) or transfusion-dependent (TD) beta-thalassemia. NTD patients will receive 12 weeks treatment with PTG-300 in escalating dose cohorts. The primary efficacy endpoint in NTD patients will be change in hemoglobin from baseline. TD patients will receive 16 weeks treatment with PTG-300 in escalating dose cohorts. The primary efficacy endpoint in TD patients will be a change in transfusion burden from baseline. All patients completing the trial will have the opportunity to participate in an open-label extension for two years. Additional information on the PTG-300 beta-thalassemia study is available at </font>https://clinicaltrials.gov/ct2/show/NCT03802201.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About PTG-300</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PTG-300 is an injectable hepcidin mimetic in clinical development for the potential treatment of beta thalassemia and polycythemia vera. Hepcidin is a natural peptide hormone that is a critical regulator governing iron absorption, recycling and utilization by the body. Iron plays an essential role in various body functions, especially blood formation. Excess iron in the body is toxic, resulting in tissue and organ damage over time. Abnormally low hepcidin levels caused by genetic mutations or secondary pathology can be addressed with a hepcidin mimetic to restore iron homeostasis. PTG-300 has been granted Orphan Drug designation in the U.S. and EU and has received Fast Track designation by the FDA for development in the treatment of beta-thalassemia. Myelodysplastic syndromes or hereditary hemochromatosis represent additional opportunities for the development of PTG-300.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\111369\19-24358-1\task9551525\24358-1-mm.htm',USER='111369',CD='Dec  3 09:22 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Protagonist Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload anemia and related rare blood diseases including beta-thalassemia and polycythemia vera. PTG-200 is an oral, gut-restricted interleukin-23 receptor specific antagonist peptide in Phase 2 clinical development for the potential treatment of inflammatory bowel disease, with Crohn&#146;s disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the potential treatment of inflammatory bowel disease, with a Phase 2 ulcerative colitis study expected to commence in the second quarter of 2020.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cautionary Note on Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential of PTG-300 as a possible treatment for TD beta-thalassemia, the Company&#146;s success at finding appropriate doses of PTG-300 for the treatment of beta-thalassemia, the results of future studies for the treatment of beta-thalassemia, the potential utility of PTG-300 in blood disorders including beta-thalassemia, polycythemia vera, and hereditary hemochromatosis, as well as myelodysplastic syndromes, the Company&#146;s ability to fund its clinical trials, results of the Phase 2 TRANSCEND Study,, the potential of PTG-200 and PN-943 as possible treatments for inflammatory bowel disease, the initiation of and enrollment of patients in our clinical trials, the results of clinical trials and the outlook for our other programs. In some cases, you can identify these statements by forward-looking words such as &#147;plan,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;potential,&#148; or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading &#147;Risk Factors&#148; contained in our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended September&nbsp;30, 2019, filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">###</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Solebury Trout</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rich Allan (media)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: +1 646-378-2958</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Email: rallan@soleburytrout.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Brian Korb (investors)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: +1 646-378-2923</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Email: bkorb@soleburytrout.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\111369\19-24358-1\task9551525\24358-1-mm.htm',USER='111369',CD='Dec  3 09:22 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g243581mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g243581mmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  X -D# 2(  A$! Q$!_\0
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MHU6W^/DBV( $VE[KP+TW9X)]^$_.IX=&^(NGPK96NMZ3=6ZC:EU<Q-YP';(
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g243581mmi002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g243581mmi002.gif
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M%6B&L'2+P  4>EK[2 A>$ 4U^8-V90@6ZIYH=P*F=5P5IGA1N*;W13 2Z&M
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MH#)_M7DXI0C^44/;]B*>Y$G5HT=DP2GT@H!MX3T[<5DX$A2.81-^QB"JM T
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M #< J9^J-ZF*D[.QI[.&D[BAM:>]OHBTP;>_Q,7%$$1/6E( 7\L06EF&S@D
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M8M@:N]Q];9\I$*(@=V[0W1#NM<OA#Z$#<Q_72TY?>].Z.L4*F( !$2#OO9<
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9=GB'>)B'>KB'?-B'?OB'@!B(@H@)@0  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g243581mmi003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g243581mmi003.gif
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M-]8C(U-GQ347@P,-8!UY5[6XHO^2!QRY(@,^;N BD?8(II ]!U%E3Q#RU7A
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M*@P9P2?6\(G)/(4#$+B\>D_*!8Z=4:(V@ P*]OKI_]I4"+0  1! @90U\%I
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M 0+0?$7PJP&6;<OY)9[X 0RV$2%HN3&3JV +I YZ$Z?KA9 WDV"XJTF  A$
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M.D[E!7*DEWOK]P,">+QD\0.3,0E,.L1-60YDBV-9U<A?YO^'*A>>ZS.Z_P<
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MW-=+F CV :N-=#9N;>L;Z_G; /$N@F:VLKB=Z?YHZ[H.LQ,[VGH)9@B<" U
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MWGU1\.V=\V)RDIV1G+3ZS"C"UT^?9:#-Q>.>KF!L])K)F4W?MK6-]8A]!"%
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
